Transplanting your own skin cells to restore pigment in vitiligo

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The procedure harvests a thin split‑thickness graft (usually from the anterolateral thigh), prepares a non‑cultured epidermal cell suspension using a commercial kit, and applies the cell suspension onto dermabraded depigmented skin under local anesthesia. It is offered to patients whose vitiligo has been stable (segmental/unclassified ≥6 months, non‑segmental ≥1 year), involves at least 5% body surface area, and has been resistant to medications and phototherapy. Participants will be followed long term to record safety outcomes and degree of repigmentation, while investigators analyze how cell density and cell types relate to clinical results. The data aim to inform how to use this autologous grafting technique in clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed as vitiligo, according to the "Vitiligo Diagnosis and Treatment Consensus (2021 edition)
* Segmental and unclassified vitiligo stable for 6 months, Non-segmental vitiligo stable for 1 year and resistant to medication and phototherapy
* BSA≥5%
* Sign the informed consent and be willing to undergo surgical treatment
* 8-65 years old, both genders

Exclusion Criteria:

* Severe visceral or infectious disease not suitable for surgical treatment
* Tendency toward keloid formation
* Coagulation defects
* Unable to complete follow-up on time

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• crisaborole 2% versus tacrolimus 0.1% with light therapy for facial vitiligo

  This study tests whether applying crisaborole 2% ointment can improve stable facial vitiligo in children and adults and whether it is as safe and effective as tacrolimus 0.1% when combined with light therapy.

  Recruiting Phase 3 Cairo University · Cairo · NCT07904910

• Imaging vitiligo lesions with polarized, sub-ultraviolet, and ultraviolet dermoscopy

  This study tests whether advanced light-based skin imaging can reveal details of vitiligo spots in adults more clearly than standard polarized dermoscopy.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07846969

• MH004 Ointment in non-segmental vitiligo: a phase 3 trial

  A 12-month randomized trial tests MH004 ointment to see if it helps facial vitiligo more than a placebo in people aged 12 to 75.

  Recruiting Phase 3 Minghui Pharmaceutical (Hangzhou) Ltd · Beijing, Beijing Municipality · NCT07682506

• NSV: Vitiligo Drug Safety and Effectiveness Registry for Adults and Teens

  This registry tracks adults and teens with nonsegmental vitiligo to see how usual treatments work and how safe they are over time in real-world dermatology care.

  Recruiting CorEvitas · Waltham, Massachusetts · NCT07659418

• D-2570 in Non-Segmental Vitiligo (Phase 2)

  This study tests whether D-2570 can improve skin discoloration in adults with non-segmental vitiligo compared with a placebo.

  Recruiting Phase 2 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07625891

• LY4005130 for adults with non-segmental vitiligo

  This study will test whether intravenous LY4005130 is safe and what side effects it may cause in adults with non-segmental vitiligo.

  Recruiting at 35 sites Phase 2 Eli Lilly and Company · Phoenix, Arizona and 34 other locations · NCT07533019

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.